VTYX
Ventyx Biosciences Inc
Ventyx Biosciences Inc historical holders
total: 1
Third Point Ventyx Biosciences Inc transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q4
- Held for:
- 5 quarters
- Latest activity:
- 2023 Q1
Daniel Loeb has been an institutional investor in Ventyx Biosciences Inc (VTYX) since 2021 Q4. According to 2026 Q1 report, Daniel Loeb doesn't hold any shares. The fund/company first acquired VTYX in 2021 Q4, initially purchasing about 4.31M shares. Since the initial investment, Third Point has made 2 more transactions in this position.
When did Daniel Loeb exit their VTYX position?
Daniel Loeb no longer holds Ventyx Biosciences Inc (VTYX). They sold off their entire position in 2023 Q1, closing out an investment that began in 2021 Q4.
When did Daniel Loeb first invest in VTYX?
Daniel Loeb first invested in Ventyx Biosciences Inc (VTYX) in 2021 Q4 at the reported quarter-end price of $19.26 per share, acquiring 4,312,834 shares in their initial purchase.
What is Daniel Loeb's average cost basis for VTYX?
Based on historical transaction data, Daniel Loeb's estimated cost basis for Ventyx Biosciences Inc (VTYX) is approximately $19.26 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $19.26
- Weighted AVG sell price:
- $32.79
VTYX transactions history by Third Point
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q1
|
0.00%
|
0
|
$32.79
|
|
-100% (-1,000,000)
|
-0.55%
|
|
2022 Q4
|
0.55%
|
1,000,000
|
$32.79
|
$32,790,000
|
-76.81% (-3,312,834)
|
-1.96%
|
|
2021 Q4
|
0.58%
|
4,312,834
|
$19.26
|
$83,083,000
|
new
|
+0.58%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.